03 Sep ASCEND T1D
The ASCEND T1D Study is testing anti-thymocyte globulin (ATG) and teplizumab to compare their ability to delay the onset of type 1 diabetes (T1D) in people at high risk.
A previous TrialNet study of teplizumab in people at high risk found it can delay clinical diagnosis by 2+ years. This study was instrumental in the FDA’s approval of teplizumab as the first treatment to delay T1D progression.
Another TrialNet study for people newly diagnosed with T1D found ATG improved insulin production and hemoglobin A1c (an indicator of long-term blood sugar levels) for 2 years.
If the ASCEND T1D Study finds ATG is comparable to teplizumab in delaying T1D in people at high risk, TrialNet may conduct an extension study to further test ATG’s ability to slow disease progression.
Learn more at https://www.benaroyaresearch.org/our-research/clinical-research-vmfh/ascend-t1d
Participant Eligibility
The following people may be eligible:
-Ages 4 to 34
-Stage 2 T1D confirmed by TrialNet testing (at least 2 diabetes-related autoantibodies and abnormal glucose tolerance)
-Not diagnosed with Stage 3 T1D (clinical diagnosis)
A research team member will go over the full list of eligibility criteria with you.
Contact
the Outreach Team
(800) 888-4187
Additional Study Details
Full Study Title
Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
Investigator(s)
Kurt Griffin, MD
Sandra Lord, MD
Accepts Healthy Volunteers?
No
Study Site(s)
Benaroya Research Institute
1201 Ninth Ave
Seattle, Washington 98101
